The identification of rearrangements driving expression of neurotrophic receptor tyrosine kinase ( ) family kinases in tumors has become critically important because of the availability of effective, specific inhibitor drugs. Whole-genome sequencing (WGS) combined with RNA sequencing (RNA-seq) can identify novel and recurrent expressed fusions. Here we describe three fusions identified in two pediatric central nervous system cancers and an extracranial solid tumor using WGS and RNA-seq. These fusions arose either through a simple balanced rearrangement or in the context of a complex chromoplexy event. We cloned the fusion directly from a patient sample and showed that enforced expression of this fusion is sufficient to promote cytokine-independent survival and proliferation. Cells transformed by expression are sensitive to a TRK inhibitor drug. We report here that fusions can arise in a range of pediatric cancers. Although WGS and RNA-seq are not required to detect fusions, these techniques may be of benefit when fusions are not suspected on clinical grounds or not identified by other methods.